Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Automated cellular imaging system III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH.

Minot DM, Kipp BR, Root RM, Meyer RG, Reynolds CA, Nassar A, Henry MR, Clayton AC.

Am J Clin Pathol. 2009 Jul;132(1):133-8. doi: 10.1309/AJCPJV0SKAF2PCMY.

PMID:
19864244
3.

Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.

Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, Fabian CJ.

Histopathology. 2006 Feb;48(3):258-67.

PMID:
16430472
4.
5.
6.

Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique.

Minot DM, Voss J, Rademacher S, Lwin T, Orsulak J, Caron B, Ketterling R, Nassar A, Chen B, Clayton A.

Am J Clin Pathol. 2012 Feb;137(2):270-6. doi: 10.1309/AJCP9MKNLHQNK2ZX.

PMID:
22261453
7.

HER2 status in breast cancer determined by IHC and FISH: comparison of the results.

Mrozkowiak A, Olszewski WP, Piaścik A, Olszewski WT.

Pol J Pathol. 2004;55(4):165-71.

PMID:
15757204
8.

Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.

Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, Jenderek C, Andergassen U, Jeschke U, Friese K.

J Cancer Res Clin Oncol. 2010 Jul;136(7):1029-37. doi: 10.1007/s00432-009-0748-4. Epub 2010 Jan 6.

PMID:
20052594
9.
10.

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.

Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Tse CC.

Mod Pathol. 2008 Oct;21(10):1271-7. doi: 10.1038/modpathol.2008.83. Epub 2008 May 16.

11.

Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.

Yosepovich A, Avivi C, Bar J, Polak-Charcon S, Mardoukh C, Barshack I.

Isr Med Assoc J. 2010 Jun;12(6):353-6.

12.

Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer.

Skaland I, Øvestad I, Janssen EA, Klos J, Kjellevold KH, Helliesen T, Baak JP.

J Clin Pathol. 2008 Jan;61(1):68-71. Epub 2007 Apr 5.

13.

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.

J Clin Oncol. 2005 Jul 1;23(19):4287-97.

PMID:
15994142
14.

Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?

Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, Kim BS, Jang SJ, Kang YK.

Hum Pathol. 2012 Mar;43(3):413-22. doi: 10.1016/j.humpath.2011.05.019. Epub 2011 Aug 19.

PMID:
21855114
15.
16.

Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.

van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling J.

Mod Pathol. 2009 Jul;22(7):879-86. doi: 10.1038/modpathol.2009.37. Epub 2009 Mar 20.

17.
18.

Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.

Tafe LJ, Allen SF, Steinmetz HB, Dokus BA, Cook LJ, Marotti JD, Tsongalis GJ.

Exp Mol Pathol. 2014 Aug;97(1):116-9. doi: 10.1016/j.yexmp.2014.06.003. Epub 2014 Jun 11.

PMID:
24927872
19.

Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.

Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.

Oncol Rep. 2008 Mar;19(3):651-6.

PMID:
18288397
20.

HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.

McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J.

Am J Clin Pathol. 2002 Jun;117(6):935-43.

PMID:
12047146

Supplemental Content

Support Center